According to the Silicon Valley Business Journal, CardioDX has set pricing terms for its IPO. The publication reports that the company plans on selling 5 million shares at a price between $14 and $16 a share. CardioDX will trade its stock on the NASDAQ under the ticker symbol “CDX.” BofA Merrill Lynch and Jefferies LLC will serve as lead underwriters. Headquartered in Palo Alto, Calif., CardioDx is a molecular diagnostics company specializing in cardiovascular genomics. Investors include V-Sciences Investments, Longitude Venture Partners, Artiman Ventures, Kleiner Perkins Caufield & Byers, JP Morgan and Mohr Davidow Ventures.